Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations
We have studied the simultaneous administration of granulocyte colony stimulating factor (G-CSF), given concomitantly with an infusion of either doxorubicin or ifosphamide--the former, both intraarterially (i.a.) and intravenously (i.v.), the latter, intravenously--to a group of patients with variou...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1997-02, Vol.20 (1), p.63-68 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 68 |
|---|---|
| container_issue | 1 |
| container_start_page | 63 |
| container_title | American journal of clinical oncology |
| container_volume | 20 |
| creator | WEISS, A. J LACKMAN, R. D |
| description | We have studied the simultaneous administration of granulocyte colony stimulating factor (G-CSF), given concomitantly with an infusion of either doxorubicin or ifosphamide--the former, both intraarterially (i.a.) and intravenously (i.v.), the latter, intravenously--to a group of patients with various malignancies. Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug. No untoward effects have been noted to date. |
| doi_str_mv | 10.1097/00000421-199702000-00014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78824208</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78824208</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-4b48f8e45e1dacbe976b629036c180130da0ad6af373725f703104033da5febb3</originalsourceid><addsrcrecordid>eNo9kF1LHDEUhkNp0dX2Jwi5KL0bzddMMpcitQqCNxZ6N5zJJLuRTLImmdb9943uuoEQDud5zyEPQpiSS0p6eUXejmC0oX0vCatFUy8Vn9CKtlw2ouV_PqMVYVI2XHJ2is5yfq5I2xF5gk76mmE9XaHX-2CX7GIAj_XGzLFsTILtDus4jy6YCf9zZYOT2dcQCt4sMwS8ThAWH_WumMr6GHY4FzcvHooLa2xBl5gwTH9rBNYmYwgT9m52pQIx5K_oiwWfzbfDe45-3_58urlrHh5_3d9cPzSaKVEaMQpllRGtoRPo0fSyGzvWE95pqgjlZAICUwe2_lKy1krCKRGE8wlaa8aRn6Mf-7nbFF8Wk8swu6yN9xBMXPIglWKCEVVBtQd1ijknY4dtcjOk3UDJ8CZ9-JA-HKUP79Jr9OKwYxlnMx2DB8u1__3Qh6zB26pOu3zEWKt4ncv_AxfujMk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78824208</pqid></control><display><type>article</type><title>Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>WEISS, A. J ; LACKMAN, R. D</creator><creatorcontrib>WEISS, A. J ; LACKMAN, R. D</creatorcontrib><description>We have studied the simultaneous administration of granulocyte colony stimulating factor (G-CSF), given concomitantly with an infusion of either doxorubicin or ifosphamide--the former, both intraarterially (i.a.) and intravenously (i.v.), the latter, intravenously--to a group of patients with various malignancies. Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug. No untoward effects have been noted to date.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199702000-00014</identifier><identifier>PMID: 9020291</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma - drug therapy ; Chemotherapy ; Clinical Trials as Topic ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; Female ; Floxuridine - administration & dosage ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Humans ; Ifosfamide - administration & dosage ; Infusions, Intra-Arterial ; Infusions, Intravenous ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Recombinant Proteins ; Sarcoma - drug therapy</subject><ispartof>American journal of clinical oncology, 1997-02, Vol.20 (1), p.63-68</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c284t-4b48f8e45e1dacbe976b629036c180130da0ad6af373725f703104033da5febb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2583042$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9020291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WEISS, A. J</creatorcontrib><creatorcontrib>LACKMAN, R. D</creatorcontrib><title>Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>We have studied the simultaneous administration of granulocyte colony stimulating factor (G-CSF), given concomitantly with an infusion of either doxorubicin or ifosphamide--the former, both intraarterially (i.a.) and intravenously (i.v.), the latter, intravenously--to a group of patients with various malignancies. Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug. No untoward effects have been noted to date.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma - drug therapy</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Floxuridine - administration & dosage</subject><subject>Granulocyte Colony-Stimulating Factor - administration & dosage</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Infusions, Intra-Arterial</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins</subject><subject>Sarcoma - drug therapy</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF1LHDEUhkNp0dX2Jwi5KL0bzddMMpcitQqCNxZ6N5zJJLuRTLImmdb9943uuoEQDud5zyEPQpiSS0p6eUXejmC0oX0vCatFUy8Vn9CKtlw2ouV_PqMVYVI2XHJ2is5yfq5I2xF5gk76mmE9XaHX-2CX7GIAj_XGzLFsTILtDus4jy6YCf9zZYOT2dcQCt4sMwS8ThAWH_WumMr6GHY4FzcvHooLa2xBl5gwTH9rBNYmYwgT9m52pQIx5K_oiwWfzbfDe45-3_58urlrHh5_3d9cPzSaKVEaMQpllRGtoRPo0fSyGzvWE95pqgjlZAICUwe2_lKy1krCKRGE8wlaa8aRn6Mf-7nbFF8Wk8swu6yN9xBMXPIglWKCEVVBtQd1ijknY4dtcjOk3UDJ8CZ9-JA-HKUP79Jr9OKwYxlnMx2DB8u1__3Qh6zB26pOu3zEWKt4ncv_AxfujMk</recordid><startdate>19970201</startdate><enddate>19970201</enddate><creator>WEISS, A. J</creator><creator>LACKMAN, R. D</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970201</creationdate><title>Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations</title><author>WEISS, A. J ; LACKMAN, R. D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-4b48f8e45e1dacbe976b629036c180130da0ad6af373725f703104033da5febb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma - drug therapy</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Floxuridine - administration & dosage</topic><topic>Granulocyte Colony-Stimulating Factor - administration & dosage</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Infusions, Intra-Arterial</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins</topic><topic>Sarcoma - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WEISS, A. J</creatorcontrib><creatorcontrib>LACKMAN, R. D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WEISS, A. J</au><au>LACKMAN, R. D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1997-02-01</date><risdate>1997</risdate><volume>20</volume><issue>1</issue><spage>63</spage><epage>68</epage><pages>63-68</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>We have studied the simultaneous administration of granulocyte colony stimulating factor (G-CSF), given concomitantly with an infusion of either doxorubicin or ifosphamide--the former, both intraarterially (i.a.) and intravenously (i.v.), the latter, intravenously--to a group of patients with various malignancies. Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug. No untoward effects have been noted to date.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>9020291</pmid><doi>10.1097/00000421-199702000-00014</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1997-02, Vol.20 (1), p.63-68 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78824208 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma - drug therapy Chemotherapy Clinical Trials as Topic Doxorubicin - administration & dosage Drug Administration Schedule Female Floxuridine - administration & dosage Granulocyte Colony-Stimulating Factor - administration & dosage Granulocyte Colony-Stimulating Factor - therapeutic use Humans Ifosfamide - administration & dosage Infusions, Intra-Arterial Infusions, Intravenous Male Medical sciences Pharmacology. Drug treatments Recombinant Proteins Sarcoma - drug therapy |
| title | Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor advantages and limitations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A36%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infusional%20chemotherapy%20combined%20with%20recombinant%20human%20granulocyte%20colony%20stimulating%20factor%20advantages%20and%20limitations&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=WEISS,%20A.%20J&rft.date=1997-02-01&rft.volume=20&rft.issue=1&rft.spage=63&rft.epage=68&rft.pages=63-68&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199702000-00014&rft_dat=%3Cproquest_cross%3E78824208%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78824208&rft_id=info:pmid/9020291&rfr_iscdi=true |